The Motley Fool

3 FTSE 100 dividend stocks paying more than GlaxoSmithKline

Image source: Getty Images.

With its defensive qualities, it’s only natural many income investors turn to FTSE 100 pharma stock GlaxoSmithKline (LSE: GSK) for dividends. What’s more, with decent Q1 figures and last year’s near-£10bn deal with US firm Pfizer helping to reduce debt, the once-precarious-looking payout looks secure.

All told, the company is forecast to return 80p per share again in 2019, which translates to a chunky 5.2% yield.

5G is here – and shares of this ‘sleeping giant’ could be a great way for you to potentially profit!

According to one leading industry firm, the 5G boom could create a global industry worth US$12.3 TRILLION out of thin air…

And if you click here we’ll show you something that could be key to unlocking 5G’s full potential...

But that’s not to say that there aren’t other, higher income opportunities elsewhere in the stock market’s top tier. Question is, are they worth the risk?

Better than Glaxo?

Glaxo’s FTSE 100 peer Legal and General (LSE: LGEN) also offers a great yield. One of the things I particularly like about the company from an income perspective is the willingness management has shown to consistently raise payouts for many years now. 

The £16bn investment management and insurance business is down to hand out 17.6p per share in the current financial year, equating to a return of almost 6.3%, safely covered by profits.

In addition to this, the diversified £17bn-cap also trades on a cheap-looking valuation at the moment due to concerns over demand for financial services if global growth were to slow. 

Based on a near-10% expected rise in profits in 2019, Legal and General can be acquired for a little under nine times earnings. That’s far less than its five-year average P/E ratio of 12.3.

Another stock that plans to return more in dividends than Glaxo is tobacco giant British American Tobacco (LSE: BATS). The owner of brands such as Dunhill and Lucky Strike is predicted to reward loyal holders with 209p per share in 2019. And with shares around the 2900p mark yesterday, that gives a yield of 7.2%, covered 1.5 times by anticipated profits. 

Why so high? Because investors continue to be bothered by the decline in the number of people smoking and the threat of further regulation. An example of the latter would be the possible banning of menthol cigarettes in the US.

With regard to the first hurdle, the growing popularity of next-generation products such as vaping should keep the cash coming in for some time to come.

Separately, and as the star fund manager Terry Smith has pointed out, not all regulation is actually bad for tobacco firms. Recent laws prohibiting advertising, for example, actually saved them a lot of cash that would otherwise be spent on marketing.

Moreover, the moat that the tobacco companies have built is sufficient to dissuade any would-be competitors from entering the industry. With this in mind, I’d be more comfortable investing in British American Tobacco over others in the FTSE 100, particularly utility stocks

On which note, a company that I’m happy to continue avoiding right now is housebuilder Persimmon (LSE: PSN), despite it boasting a simply stonking 11.2% yield for this year.

That may be more than double that offered by Glaxo but, with accusations of poor workmanship, controversial pay rewards for executives and uncertainty regarding Brexit, I think the business isn’t quite as attractive as it first appears.

Persimmon’s stock currently trades on 7.5 times earnings. While this kind of valuation would usually get value investors salivating, it’s worth highlighting cyclical stocks often look like bargains at market peaks. Personally, I think we’re already past this point. 

As such, Persimmon is the only one of the three I wouldn’t consider buying before GlaxoSmithKline.

“This Stock Could Be Like Buying Amazon in 1997”

I'm sure you'll agree that's quite the statement from Motley Fool Co-Founder Tom Gardner.

But since our US analyst team first recommended shares in this unique tech stock back in 2016, the value has soared.

What's more, we firmly believe there's still plenty of upside in its future. In fact, even throughout the current coronavirus crisis, its performance has been beating Wall St expectations.

And right now, we're giving you a chance to discover exactly what has got our analysts all fired up about this niche industry phenomenon, in our FREE special report, A Top US Share From The Motley Fool.

Click here to claim your copy now — and we’ll tell you the name of this Top US Share… free of charge!

Paul Summers has no position in any of the shares mentioned. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

Our 6 'Best Buys Now' Shares

Renowned stock-picker Mark Rogers and his analyst team at The Motley Fool UK have named 6 shares that they believe UK investors should consider buying NOW.

So if you’re looking for more stock ideas to try and best position your portfolio today, then it might be a good day for you. Because we're offering a full 33% off your first year of membership to our flagship share-tipping service, backed by our 'no quibbles' 30-day subscription fee refund guarantee.

Simply click below to discover how you can take advantage of this.